Cerebral/ Cortical Visual Impairment: Screening, Identification and Outcome Prediction in Neonates

Recruiting Observational Study
Preterm Less Than 32wks With IVH, WMI/PVL Late Preterm or Term (37-42wks) With Neonatal Encephalopathy Treated With Hypothermia for HIE
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
31 Weeks – 42 Weeks
Sex
Any
Study type
Observational
Participants needed
60 (estimated)
Sponsor
Brigham and Women's Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cerebral/Cortical Visual Impairment (CVI) is the leading cause of childhood visual impairment in the United States and other industrialized countries. CVI is a brain-based visual disorder in which visual acuity or visual fields are reduced despite a normal eye examination or greater-than-expected visual impairment relative to ocular pathology. CVI is increasingly recognized in children with neurol…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Preterm infants born \< 32 weeks gestational age with any of the following: * Germinal matrix/intraventricular hemorrhage (IVH) * White matter injury (WMI), including periventricular leukomalacia (PVL) * Late preterm infants (born 34-36 weeks gestation) or term infants (born 3…
Contacts

Mohamed El-Dib, MD

+15712016409

mel-dib@bwh.harvard.edu

CONTACT

Mohamed El-Dib

CONTACT